Investors bought shares of Pfizer Inc. (NYSE:PFE) on weakness during trading hours on Thursday. $109.87 million flowed into the stock on the tick-up and $71.13 million flowed out of the stock on the tick-down, for a money net flow of $38.74 million into the stock. Of all equities tracked, Pfizer had the 6th highest net in-flow for the day. Pfizer traded down ($0.09) for the day and closed at $35.77

PFE has been the topic of several research analyst reports. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $54.00 target price on shares of Pfizer in a research note on Sunday, March 20th. Sanford C. Bernstein reaffirmed a “buy” rating and set a $36.00 target price on shares of Pfizer in a research note on Tuesday, April 5th. Jefferies Group reaffirmed a “buy” rating and set a $39.00 target price (down previously from $42.00) on shares of Pfizer in a research note on Tuesday, April 5th. Leerink Swann reaffirmed a “hold” rating on shares of Pfizer in a research note on Tuesday, April 5th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $39.00 target price on shares of Pfizer in a research note on Tuesday, April 5th. Eight research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $38.01.

The stock has a 50-day moving average of $34.79 and a 200-day moving average of $32.09. The company has a market capitalization of $219.06 billion and a PE ratio of 29.61.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.12. The company earned $13 billion during the quarter, compared to the consensus estimate of $12 billion. The firm’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.51 earnings per share. Equities research analysts anticipate that Pfizer Inc. will post $2.44 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 1st. Shareholders of record on Friday, August 5th will be paid a $0.30 dividend. The ex-dividend date is Wednesday, August 3rd. This represents a $1.20 dividend on an annualized basis and a yield of 3.32%.

In other news, EVP Frank A. Damelio sold 100,000 shares of Pfizer stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $34.49, for a total transaction of $3,449,000.00. Following the completion of the transaction, the executive vice president now directly owns 472,994 shares in the company, valued at approximately $16,313,563.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Loretta V. Cangialosi sold 86,000 shares of Pfizer stock in a transaction that occurred on Tuesday, May 24th. The stock was sold at an average price of $33.97, for a total value of $2,921,420.00. Following the transaction, the vice president now owns 271,663 shares of the company’s stock, valued at $9,228,392.11. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have modified their holdings of the company. Russell Frank Co increased its position in shares of Pfizer by 27.5% in the fourth quarter. Russell Frank Co now owns 18,078,424 shares of the biopharmaceutical company’s stock valued at $592,129,000 after buying an additional 3,899,607 shares in the last quarter. Hexavest Inc. increased its position in shares of Pfizer by 14.2% in the fourth quarter. Hexavest Inc. now owns 6,280,381 shares of the biopharmaceutical company’s stock valued at $202,731,000 after buying an additional 782,911 shares in the last quarter. North Star Asset Management Inc. increased its position in shares of Pfizer by 2.1% in the fourth quarter. North Star Asset Management Inc. now owns 251,048 shares of the biopharmaceutical company’s stock valued at $8,103,000 after buying an additional 5,089 shares in the last quarter. Hudock Capital Group LLC increased its position in shares of Pfizer by 0.9% in the fourth quarter. Hudock Capital Group LLC now owns 54,030 shares of the biopharmaceutical company’s stock valued at $1,744,000 after buying an additional 508 shares in the last quarter. Finally, Transamerica Financial Advisors Inc. increased its position in shares of Pfizer by 6.0% in the fourth quarter. Transamerica Financial Advisors Inc. now owns 145,101 shares of the biopharmaceutical company’s stock valued at $4,684,000 after buying an additional 8,218 shares in the last quarter.

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.